Parthenon Therapeutics invents a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment and penetrate barriers that exclude immune cells. Its lead program, PRTH-101, targets discoidin domain receptor 1 (DDR1) to disrupt the tumor extracellular matrix and promote immune cell infiltration. The company plans to use its newly raised capital to advance these programs and build a portfolio of drug candidates aimed at treating multiple cancer types. Parthenon’s approach is supported by a peer-reviewed Nature publication describing DDR1’s role in stabilizing the tumor ECM and correlating DDR1 expression with reduced intratumoral T cells. Leadership emphasizes translating these molecular insights into fit-for-purpose therapeutics to address immune exclusion, stromal fibrosis, and related barriers. The company highlights collaborations with academic co-authors and an expert Scientific Advisory Board to guide development.

Total raised

$65M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2021